These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 8594425)

  • 1. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
    N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    Decousus H; Leizorovicz A; Parent F; Page Y; Tardy B; Girard P; Laporte S; Faivre R; Charbonnier B; Barral FG; Huet Y; Simonneau G
    N Engl J Med; 1998 Feb; 338(7):409-15. PubMed ID: 9459643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
    Hull RD; Raskob GE; Pineo GF; Green D; Trowbridge AA; Elliott CG; Lerner RG; Hall J; Sparling T; Brettell HR
    N Engl J Med; 1992 Apr; 326(15):975-82. PubMed ID: 1545850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression.
    Labas P; Ohrádka B; Vladimír J; Cambal M
    Int Angiol; 2000 Dec; 19(4):303-7. PubMed ID: 11305727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
    Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
    Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
    N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF; Neuhart E
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
    Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalteparin versus unfractionated heparin in critically ill patients.
    ; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
    N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
    N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    Montalescot G; White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    N Engl J Med; 2006 Sep; 355(10):1006-17. PubMed ID: 16957147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
    Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
    N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.